De Gri Fis Therapeutics Inc. (4576) Earnings Report: Net Sales Down 80.9% YoY, Operating Loss of 312 Million Yen

De Gri Fis Therapeutics Inc. (4576) released its financial results, reporting net sales down 80.9% YoY to 33 million yen. On the profit side, the company posted an operating loss of 312 million yen, an ordinary loss of 322 million yen, and a net loss attributable to owners of the parent of 323 million yen. Basic earnings per share (EPS) stood at -5.8 yen.

From a financial structure perspective, the equity ratio is maintained at a relatively solid 68.7%, indicating a sound capital base. Meanwhile, interest-bearing debt stands at 580 million yen, retained earnings at -540 million yen, operating cash flow at -490 million yen, free cash flow at -500 million yen, and cash and cash equivalents at 0.99 billion yen. These figures reflect the characteristics of a research-and-development-driven biotech enterprise, and market participants will continue to monitor future pipeline progress and financial developments.